China’s Greater Bay Area: Living up to the Hype?
A decade on from its launch, the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) initiative has made some significant wins but remains some way from fulfilling the vision of a fully…
Address: Ocean Towers 15th Floor, 550 Yanan East Road, Shanghai ,China
Tel: +86 21 5306 0001
Web: http://www.zuelligpharma.com/
Zuellig Pharma was first established in Asia over 60 years ago and has become the leading healthcare distribution solution specialist in 15 countries and regions in Asia. Zuellig Pharma combines regional market expertise with constantly evolving quality services, IT systems, facilities and management in order to create enduring market partnerships based on trust, open communication, responsiveness, vision and top results.
In the past six decades, Zuellig Pharma has built up extensive experience in Asia Pacific, meeting the ever-changing needs of the market place through continuous innovation, efficiency and forward looking management. By combining extensive local market expertise with global vision and the latest technological developments Zuellig Pharma provides dedicated, cutting-edge distribution solutions to the healthcare industry. Zuellig Pharma’s state-of-the art facilities operate in strict accordance with rigorous quality management standards and set industry benchmarks for excellence.
Distribution services
A decade on from its launch, the Guangdong-Hong Kong-Macao Greater Bay Area (GBA) initiative has made some significant wins but remains some way from fulfilling the vision of a fully…
Writing in the September 2023 edition of DIA’s Global Forum magazine, Shuting Li of Anhui Jimin Cancer Hospital and Xinfang Fan of Bayer Health Care Ltd. examine how Chinese clinical…
Ongoing geopolitical tensions between China and the West have led the G7 group of countries to warn of the threat of “economic coercion” from China and the US to scrutinise…
A roundup of some of the latest healthcare and pharma news from China including a crackdown on healthcare corruption; AstraZeneca’s cardiovascular mortality drug approval and mRNA manufacturing deal with CanSino;…
Writing in the August edition of DIA’s Global Forum magazine, Wen Yin of the Pfizer China R&D Center and Wanhe Deng of GSK China Investment look back on four years…
At a time when the country’s economy has fallen into a slump with the currency sinking to its lowest level in 16 years, Chinese giant Fosun Pharma continues to agressively…
A roundup of some of the biggest recent stories coming out of China, including the commerce minister’s peace offering to international drug companies; CSPC Pharmaceutical Group’s partnership with Pfizer; Merck’s…
A roundup of some of the most significant recent stories from the Chinese pharmaceutical industry, including a slate of international investment which seems to suggest that – despite ongoing political…
Bridge Consulting examines the opportunities and challenges ahead for China’s mRNA vaccine industry in the post-COVID era. Having eschewed foreign-made mRNA products from Pfizer/BioNTech and Moderna during the peak of…
The latest healthcare and life sciences news from China, including Eisai’s USD 2 billion oncology deal with Bliss Biopharma; Hasten Biopharmaceutic acquisition of commercial rights in China for Rocephin from…
China has made major healthcare strides over the past decade with regulatory reforms, infrastructure improvements, and the advancement of universal healthcare. While the COVID-19 pandemic revealed the need for further…
The latest news from the Chinese healthcare and life sciences industry, including the first public comments from Astellas CEO Naoki Okamura following an employee’s arrest on espionage charges in China,…
See our Cookie Privacy Policy Here
